IRIS
TACCONELLI, Stefania
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.385
EU - Europa 3.370
AS - Asia 2.869
SA - Sud America 341
AF - Africa 48
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 6
Totale 11.027
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.294
SG - Singapore 1.065
CN - Cina 1.029
UA - Ucraina 529
IT - Italia 509
IE - Irlanda 507
GB - Regno Unito 422
SE - Svezia 365
TR - Turchia 357
FR - Francia 334
BR - Brasile 300
DE - Germania 226
FI - Finlandia 136
PL - Polonia 123
IN - India 108
VN - Vietnam 102
RU - Federazione Russa 97
HK - Hong Kong 46
CA - Canada 45
MX - Messico 39
JP - Giappone 29
CZ - Repubblica Ceca 27
SA - Arabia Saudita 25
ZA - Sudafrica 24
BE - Belgio 23
AR - Argentina 20
ES - Italia 20
BD - Bangladesh 19
KR - Corea 17
AT - Austria 14
ID - Indonesia 12
AE - Emirati Arabi Uniti 11
LT - Lituania 11
NL - Olanda 11
IQ - Iraq 9
IR - Iran 8
MA - Marocco 7
PK - Pakistan 7
AU - Australia 5
EC - Ecuador 5
EU - Europa 5
LY - Libia 5
BY - Bielorussia 4
CO - Colombia 4
EG - Egitto 4
VE - Venezuela 4
CL - Cile 3
GR - Grecia 3
IL - Israele 3
UZ - Uzbekistan 3
AZ - Azerbaigian 2
BN - Brunei Darussalam 2
CH - Svizzera 2
DZ - Algeria 2
HN - Honduras 2
JM - Giamaica 2
JO - Giordania 2
MY - Malesia 2
OM - Oman 2
PH - Filippine 2
PS - Palestinian Territory 2
PY - Paraguay 2
RO - Romania 2
TH - Thailandia 2
TN - Tunisia 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BB - Barbados 1
CG - Congo 1
DM - Dominica 1
EE - Estonia 1
GA - Gabon 1
GT - Guatemala 1
GY - Guiana 1
HR - Croazia 1
KE - Kenya 1
KZ - Kazakistan 1
NG - Nigeria 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PE - Perù 1
PT - Portogallo 1
TW - Taiwan 1
UY - Uruguay 1
Totale 11.027
Salva come PNG Salva come JPEG
Città #
Singapore 769
Chandler 662
Jacksonville 583
Dublin 498
Dallas 334
Southend 312
Ashburn 295
Beijing 264
Princeton 220
Dearborn 182
Izmir 170
Nanjing 155
Los Angeles 129
Wilmington 101
Kraków 98
Cambridge 96
Tongling 84
Chieti 83
Altamura 79
The Dalles 71
New York 69
Ann Arbor 67
Santa Clara 65
Nanchang 64
Boardman 53
Munich 50
Buffalo 46
Hong Kong 44
Shenyang 42
Woodbridge 38
Council Bluffs 34
Redondo Beach 34
São Paulo 34
Ho Chi Minh City 30
Hebei 29
Tianjin 29
Changsha 28
Grevenbroich 27
Hefei 27
Pescara 27
Hanoi 26
Helsinki 25
Jiaxing 24
Warsaw 24
Brno 22
Montreal 22
Riyadh 22
Chicago 21
Kocaeli 21
Seattle 21
Washington 21
Brussels 20
Kunming 20
Tokyo 20
Camerino 19
Brooklyn 17
Denver 17
Hangzhou 17
Houston 17
Orange 17
Seoul 17
Shanghai 17
Mexico City 16
Phoenix 16
Rome 16
Spoltore 16
Atlanta 15
Johannesburg 15
Norwalk 15
Nuremberg 15
Orem 14
Poplar 14
Chennai 13
Stockholm 13
Düsseldorf 12
Ankara 11
Jinan 11
Lappeenranta 11
Leawood 11
Belo Horizonte 10
Boston 10
Lanzhou 10
Mumbai 10
Toronto 10
Dong Ket 9
Guangzhou 9
Manchester 9
Augusta 8
Charlotte 8
London 8
Montesilvano 8
Romola 8
Turku 8
Vienna 8
Cape Town 7
Menlo Park 7
Rio de Janeiro 7
Amsterdam 6
Brasília 6
Dubai 6
Totale 6.875
Salva come PNG Salva come JPEG
Nome #
“DERIVATI ISOSSAZOLICI E LORO IMPIEGO COME INIBITORI DELLA CICLOOSSIGENASI” 215
Low-dose aspirin acetylates cyclooxygenase-1 in human colorectal mucosa: implications for the chemoprevention of colorectal cancer. 157
Response to "Pharmacodynamic Interaction Between Aspirin and Ibuprofen: A Plausible Mechanism of Aspirin Resistance" 143
Reduced variability to aspirin antiplatelet effect by the coadministration of statins in high-risk patients for cardiovascular disease. 139
Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action 138
Antithrombotic Agents and Cancer 137
The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. 131
Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts. 130
Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro. 128
ROLE OF DOSE POTENCY IN THE PREDICTION OF RISK OF MYOCARDIAL INFARCTION ASSOCIATED WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN THE GENERAL POPULATION. 127
Dysregulated post-transcriptional control of COX-2 gene expression in gestational diabetic endothelial cells 127
Platelet-specific deletion of cyclooxygenase-1 ameliorates dextran sulfate sodium-induced colitis in mice. 127
Effects of estrogen on endothelial prostanoid production and cyclooxygenase-2 and heme oxygenase-1 expression. 126
Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease 124
Grand challenges in pharmacotherapy of inflammation for the first decades of the 21st century. 123
Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences 122
miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction. 121
New insights into COX-2 biology and inhibition. 117
Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. 114
Measurement of 8-iso-prostaglandin F2alpha in biological fluids as a measure of lipid peroxidation 114
Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors. 112
PROSTAGLANDIN E2-MEDIATED ACTIVATION OF PHOSPHATIDYLINOSITOL 3-OH KINASE DIFFERENTIALLY AFFECTS IL-10 AND IL-1β PRODUCTION IN BLOOD CELLS. 111
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease 111
Clinical pharmacology of selective COX-2 inhibitors. 111
Oxidative stress and platelet activation in essential hyperytension 109
Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo. 109
ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS 109
THE SELECTIVITY OF NOVEL COX-2 INHIBITORS IN HUMAN WHOLE BLOOD ASSAYS OF COX-ISOZYME ACTIVITY. 108
Platelet activation in patients with colorectal cancer. 108
Modulation of prostaglandin h synthase-2 (pghs-2) expression in human monocytes by glucocorticoids. 107
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects 107
LOW-DOSE NAPROXEN INTERFERES WITH THE ANTIPLATELET EFFECT OF LOW-DOSE ASPIRIN IN HEALTHY SUBJECTS. 106
Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract. 106
INIBITORI SELETTIVI DI COX-2: LE NUOVE MOLECOLE 104
Mechanistic and pharmacological issues of aspirin as an anticancer agent 104
Cardiovascular effects of valdecoxib: transducing human pharmacology results into clinical read-outs. 102
Incomplete suppression of platelet COX-1 activity associated with aspirin-resistant thromboxane biosynthesis in acute coronary syndromes 102
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. non-selective COX-2 inhibitors 102
The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. 101
Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects 101
Gut microbiota, host gene expression, and aging. 101
Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects. 101
Risk management profile of etoricoxib: An example of personalized medicine 101
CLINICAL PHARMACOLOGY OF CYCLOOXYGENASE INHIBITION BY NAPROXEN AND LOW-DOSE ASPIRIN. 100
OXIDATIVE STRESS AND PLATELET ACTIVATION IN HUMAN ESSENTIAL HYPERTENSION. 100
CYCLOOXYGENASE-2-DERIVED PROSTACYCLIN RESTRAIN PLATELET THROMBOXANE BIOSYNTHESIS IN TOLL-LIKE RECEPTOR 4 POLYMORPHISM 100
Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. 100
Clinical pharmacology of novel selective COX-2 inhibitors. 99
De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. 99
Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. 99
Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. 98
Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis. 98
Determinants of platelet activation in human essential hypertension. 98
Effects of Acetaminophen on Constitutive and Inducible Prostanoid Biosynthesis in Human Blood Cells in vitro 97
Dose- Dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. 96
Clinical pharmacology of etoricoxib. 96
NSAIDs and cardiovascular disease. 96
NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population. 95
Pharmacological Characterization of the Microsomal Prostaglandin E2 Synthase-1 Inhibitor AF3485 In Vitro and In Vivo 95
The human pharmacology of monocyte cyclooxygenase 2 inhibition by cortisol and synthetic glucocorticoids. 94
“DIARILISOSSAZOLI FUNZIONALIZZATI INIBITORI DELLA CICLOSSIGENASI” 93
Variability in the Response to Non-Steroidal Anti-Inflammatory Drugs: Mechanisms and Perspectives. 93
EFFECTS OF CELECOXIB ON SYSTEMIC MARKERS OF PROSTANOID GENERATION AND INFLAMMATION AND ANGIOGENESIS IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS: A BIOMARKER CLINICAL STUDY. 92
Enhanced thromboxane biosynthesis in patients with colorectal and lung cancer 92
“ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS" 91
Pharmacodynamic of cyclooxygenase inhibitors in humans. 91
Biomarkers of Response to Low-Dose Aspirin in Familial Adenomatous Polyposis Patients 90
Celecoxib, ibuprofen and the antiplatelet effect of aspirin in patients with osteoarthritis and chronic stable angina 90
Inflammation and Cancer: From the Development of Personalized Indicators to Novel Therapeutic Strategies 90
Characterization of cyclooxygenase-2 acetylation and prostanoid inhibition by aspirin in cellular systems 89
CLINICAL PHARMACOLOGY OF PLATELET COX INHIBITION BY NAPROXEN AND LOW-DOSE ASPIRIN. 87
Antiplatelet Agents Affecting GPCR Signaling Implicated in Tumor Metastasis 87
DIFFERENTIAL ASSOCIATION BETWEEN HUMAN PROSTACYCLIN RECEPTOR POLYMORPHISMS AND THE DEVELOPMENT OF VENOUS THROMBOSIS AND INTIMAL HYPERPLASIA: A CLINICAL BIOMARKER STUDY. 85
P2Y12 Receptors in Tumorigenesis and Metastasis 85
Pharmacological characterization of the biosynthesis of prostanoids and hydroxyeicosatetraenoic acids in human whole blood and platelets by targeted chiral lipidomics analysis 84
Reduced thromboxane biosynthesis in carriers of Toll-like receptor 4 polymorphisms in vivo 83
The antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia 83
Managing the adverse effects of nonsteroidal anti-inflammatory drugs. 83
ENHANCED CORTISOL SECRETION DOES NOT CONTROL ASPIRIN-INSENSITIVE THROMBOXANE BIOSYNTHESIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES 82
Tumor-Educated Platelet Extracellular Vesicles: Proteomic Profiling and Crosstalk with Colorectal Cancer Cells 81
Parmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects 81
Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal. 79
Human pharmacology of naproxen sodium. 79
INCREASED OXIDATIVE STRESS IN RENOVASCULAR HYPERTENSION. 78
INHIBITION OF INDUCILE CYCLOOXYGENASE ACTIVITY BY GLUCOCORTICOIDS IN MAN. 78
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. non-selective COX-2 inhibitors 78
Biology and pharmacology of platelet-type 12-lipoxygenase in platelets, cancer cells, and their crosstalk 77
ENHANCED CORTISOL SECRETION DOES NOT CONTROL ASPIRIN-INSENSITIVE THROMBOXANE BIOSYNTHESIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES. 77
EFFECTS OF ACETAMINOPHEN ON CONSTITUTIVE AND INDUCILE PROSTANOID BIOSYNTHESIS IN HUMAN BLOOD CELLS IN VITRO. 77
ISOPROSTANES: ARE THEY MORE THAN PHYSIOPATHOLOGICAL BIOMARKERS OF LIPID PEROXIDATION? RESPONSE. 77
Effects of vitamin E supplementation on F2-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. 77
Functionalized diarylisoxazoles inhibitors of ciclooxygenase 77
Correlazione tra aumentata secrezione di cortisolo e marker di infiammazione nei pazienti con sindromi coronariche acute 76
EFFECTS OF ACETAMINOPHEN ON CONSTITUTIVE AND INDUCIBLE PROSTANOID BIOSYNTHESIS IN HUMAN BLOOD CELLS. 75
Enlarging the NSAIDs family: ether, ester and acid derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents. 75
Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: a clinical biomarker study. 74
Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. 74
Multifaceted Functions of Platelets in Cancer: From Tumorigenesis to Liquid Biopsy Tool and Drug Delivery System 74
OXIDANT STRESS AND PLATELET ACTIVATION IN ESSENTIAL HYPERTENSION. 72
Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. 71
Totale 10.030
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.942
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.942
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021456 0 0 0 0 0 129 29 23 51 124 47 53
2021/2022489 7 11 14 132 16 5 16 43 45 14 56 130
2022/20231.732 124 220 78 223 165 347 100 136 230 21 30 58
2023/2024808 52 31 69 25 63 225 183 23 5 19 9 104
2024/20251.792 123 272 198 43 52 98 66 141 152 98 219 330
2025/20262.452 443 250 526 672 471 90 0 0 0 0 0 0
Totale 11.494